JP2015518000A - 癌の化学療法剤の投与に関連した副作用の処置のための組成物及び方法 - Google Patents

癌の化学療法剤の投与に関連した副作用の処置のための組成物及び方法 Download PDF

Info

Publication number
JP2015518000A
JP2015518000A JP2015505934A JP2015505934A JP2015518000A JP 2015518000 A JP2015518000 A JP 2015518000A JP 2015505934 A JP2015505934 A JP 2015505934A JP 2015505934 A JP2015505934 A JP 2015505934A JP 2015518000 A JP2015518000 A JP 2015518000A
Authority
JP
Japan
Prior art keywords
composition
adenine
orotic acid
cancer
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015505934A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015518000A5 (enExample
Inventor
フォード，ジョン，ピー．
Original Assignee
アシンメトリック セラピューティクス，エルエルシー
アシンメトリック セラピューティクス，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/446,328 external-priority patent/US8653090B2/en
Application filed by アシンメトリック セラピューティクス，エルエルシー, アシンメトリック セラピューティクス，エルエルシー filed Critical アシンメトリック セラピューティクス，エルエルシー
Publication of JP2015518000A publication Critical patent/JP2015518000A/ja
Publication of JP2015518000A5 publication Critical patent/JP2015518000A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015505934A 2012-04-13 2013-04-12 癌の化学療法剤の投与に関連した副作用の処置のための組成物及び方法 Pending JP2015518000A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/446,328 US8653090B2 (en) 2008-03-12 2012-04-13 Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents
US13/446,328 2012-04-13
PCT/US2013/036326 WO2013155385A1 (en) 2012-04-13 2013-04-12 Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents

Publications (2)

Publication Number Publication Date
JP2015518000A true JP2015518000A (ja) 2015-06-25
JP2015518000A5 JP2015518000A5 (enExample) 2016-06-09

Family

ID=49328189

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015505934A Pending JP2015518000A (ja) 2012-04-13 2013-04-12 癌の化学療法剤の投与に関連した副作用の処置のための組成物及び方法

Country Status (5)

Country Link
EP (1) EP2836217A4 (enExample)
JP (1) JP2015518000A (enExample)
CN (1) CN104394872A (enExample)
IN (1) IN2014DN09546A (enExample)
WO (1) WO2013155385A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10736557B2 (en) 2016-03-30 2020-08-11 Brain F.I.T. Imaging, LLC Methods and magnetic imaging devices to inventory human brain cortical function
US11337631B2 (en) 2017-10-03 2022-05-24 Brainn F.I.T. Imaging, LLC Methods and magnetic imaging devices to inventory human brain cortical function
EP3946034A4 (en) 2019-04-03 2023-01-11 Brain F.I.T. Imaging, LLC METHODS AND MAGNETIC TOMOGRAPHY DEVICES FOR THE INVENTORY OF CORCOAL FUNCTION OF THE HUMAN BRAIN

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007508299A (ja) * 2003-10-10 2007-04-05 ジョン ピー． フォード， 全身性抗癌治療の間の器官保護のための方法、組成物、およびキット
JP2007522182A (ja) * 2004-02-12 2007-08-09 イスティチュート スペリオーレ ディ サニータ プロトンポンプ阻害剤の新規使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6130035A (en) * 1998-02-20 2000-10-10 Brusilow Enterprise Llc Use of orotidine monophosphate decarboxylase inhibition in a method for cancer screening
US6995165B2 (en) * 2002-02-12 2006-02-07 Ford John P Methods, compositions, and kits for organ protection during systemic anticancer therapy
US8034823B2 (en) * 2005-02-22 2011-10-11 Savvipharm Inc Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
US7470672B2 (en) * 2006-07-31 2008-12-30 Savvipharm Inc. Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007508299A (ja) * 2003-10-10 2007-04-05 ジョン ピー． フォード， 全身性抗癌治療の間の器官保護のための方法、組成物、およびキット
JP2007522182A (ja) * 2004-02-12 2007-08-09 イスティチュート スペリオーレ ディ サニータ プロトンポンプ阻害剤の新規使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2000, 26(7), P.695-708, JPN6016048763, ISSN: 0003464597 *
JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, VOL.90, NO. 6, P.667-680, JPN6016048765, ISSN: 0003464598 *
谷口 敦夫: "アデニンホスホリボシルトランスフェラーゼ欠損症 adenine phosphoribosyltransferase deficiency", 日本臨床（別冊）領域別症候群シリーズ３３ 先天異常症候群−辞典−（上）、１９９８年、第４６４〜４６６, JPN6016048768, ISSN: 0003464599 *

Also Published As

Publication number Publication date
CN104394872A (zh) 2015-03-04
EP2836217A1 (en) 2015-02-18
EP2836217A4 (en) 2015-10-28
IN2014DN09546A (enExample) 2015-07-17
WO2013155385A1 (en) 2013-10-17

Similar Documents

Publication Publication Date Title
US11077078B2 (en) Compositions and methods for the treatment of cancer
US9764029B2 (en) Tumor proliferation inhibitor containing ultrasound-sensitive substance and method for inhibiting tumor proliferation by using tumor proliferation inhibitor and low-intensity pulsed ultrasound waves
US20220145304A1 (en) Modified micrornas and their use in the treatment of cancer
WO2010088564A2 (en) Compositions and methods for the treatment of cancer
US8653090B2 (en) Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents
CN107375934B (zh) 含有果糖-1，6-二磷酸的组合物在制备抗肿瘤药物中的应用
AU2001242581A1 (en) Combination therapies with vascular damaging activity
US9119855B2 (en) Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents
WO2013155385A1 (en) Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents
US20220339175A1 (en) Application of Stachyose in Preparation of Drug for Treating Castration-Resistant Prostate Cancer
US20090232884A1 (en) Composition and method for treatment of the side-effects associated with administration of cancer chemotherapeutic agents
CN107698639A (zh) 一类吉西他滨磷酸酯的n‑甲酸酯乏氧活化前药及其应用
ES2842376T3 (es) Composición farmacéutica con capecitabina, gimeracil y oteracil para tratar el cáncer, y uso de la misma
EP2665489B1 (en) A combination comprising an adenoviral vector having a thymidine kinase gene, ganciclovir and temozolomide for use in the treatment of glioblastoma multiform
CN121668181A (zh) 一种卡培他滨与五环三萜类化合物的组合物及其在制备抗肿瘤药物中的应用
Wagner et al. Liposome dependent delivery of S‐adenosyl Methionine to cells by liposomes: A potential treatment for liver disease
RU2482855C2 (ru) Противоопухолевое средство, включающее производное цитидина и карбоплатин
HK1161971B (en) A capsule preparation containing tegafur, gimeracil and oteracil potassium
HK1161971A1 (en) A capsule preparation containing tegafur, gimeracil and oteracil potassium

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160411

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170519

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170703